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BACKGROUND
Arterial calcifications are associated with increased cardiovascular risk, but the ge-
netic basis of this association is unclear.
METHODS
We performed clinical, radiographic, and genetic studies in three families with symp-
tomatic arterial calcifications. Single-nucleotide-polymorphism analysis, targeted 
gene sequencing, quantitative polymerase-chain-reaction assays, Western blotting, 
enzyme measurements, transduction rescue experiments, and in vitro calcification 
assays were performed.
RESULTS
We identified nine persons with calcifications of the lower-extremity arteries and 
hand and foot joint capsules: all five siblings in one family, three siblings in an-
other, and one patient in a third family. Serum calcium, phosphate, and vitamin D 
levels were normal. Affected members of Family 1 shared a single 22.4-Mb region 
of homozygosity on chromosome 6 and had a homozygous nonsense mutation 
(c.662C→A, p.S221X) in NT5E, encoding CD73, which converts AMP to adenosine. 
Affected members of Family 2 had a homozygous missense mutation (c.1073G→A, 
p.C358Y) in NT5E. The proband of Family 3 was a compound heterozygote for 
c.662C→A and c.1609dupA (p.V537fsX7). All mutations found in the three families 
result in nonfunctional CD73. Cultured fibroblasts from affected members of Fam-
ily 1 showed markedly reduced expression of NT5E messenger RNA, CD73 protein, 
and enzyme activity, as well as increased alkaline phosphatase levels and accumu-
lated calcium phosphate crystals. Genetic rescue experiments normalized the CD73 
and alkaline phosphatase activity in patients’ cells, and adenosine treatment reduced 
the levels of alkaline phosphatase and calcification.
CONCLUSIONS
We identified mutations in NT5E in members of three families with symptomatic 
arterial and joint calcifications. This gene encodes CD73, which converts AMP to 
adenosine, supporting a role for this metabolic pathway in inhibiting ectopic tissue 
calcification. (Funded by the National Human Genome Research Institute and the 
National Heart, Lung, and Blood Institute of the National Institutes of Health.)
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Vascular calcification, arising ei-ther in the intima or media of vessels, is associated with an excess risk of cardio-
vascular events.1,2 This was initially considered a 
passive response to degenerative events, but mount-
ing evidence suggests it is the result of a process 
that mimics active bone remodeling.3,4 Extracel-
lular calcification is increasingly viewed as arising 
from a default biochemical pathway and requir-
ing the constant stimulation of inhibitory systems 
to prevent its occurrence.
Only a single mendelian disorder of isolated 
vascular calcification — idiopathic infantile arte-
rial calcification, now also referred to as gener-
alized arterial calcification of infancy — has been 
described.5 This autosomal recessive disease, due 
to mutations in the ectonucleotide pyrophospha-
tase–phosphodiesterase 1 gene (ENPP1), often re-
sults in death during childhood, apparently ow-
ing to disruption of the trophic influences that 
inhibit vascular-cell calcification. We conducted a 
study to evaluate an adult-onset disorder in three 
families whose affected members had extensive 
calcifications of the lower-extremity arteries and 
small joint capsules and to investigate a possible 
genetic basis of the symptoms.
Me thods
Patients
Three families were studied. Members of Family 
1 and Family 3 were admitted to the National In-
stitutes of Health (NIH) Undiagnosed Diseases 
Program and enrolled in clinical studies whose 
protocols had been approved by the institutional 
review board of the National Human Genome Re-
search Institute. The genetic studies for Family 2 
were approved by the institutional review board of 
Azienda Ospedaliera Universitaria San Giovanni 
Battista. All subjects provided written informed 
consent.
Fibroblast-Cell Cultures
Fibroblast cultures were prepared from a 4-mm 
punch-biopsy skin specimen obtained from each 
patient and grown in Dulbecco’s modified Eagle’s 
medium containing 10% fetal-calf serum and 1% 
penicillin–streptomycin, as previously described.6 
Cells were fed every other day and split 1:2 at con-
fluence.
Analysis of single-nucleotide polymorphisms 
(SNPs)
Genomic DNA in Family 1 was isolated from pe-
ripheral leukocytes and genotyped on a genotyp-
ing array (Human 1M Duo, Illumina). Homozy-
gosity-allele plots were generated with the use of 
GenomeStudio software. Anomalous regions of 
homozygosity were identified visually and con-
firmed by means of haplotype imputation (ENT 
program). A lod score was established with the 
use of parametric multipoint linkage analysis, as 
previously described.7
Mutation Analysis of CD73
Coding exons and intron–exon junctions of NT5E 
were amplified with the use of a touchdown poly-
merase-chain-reaction (PCR) assay of 50 ng of 
genomic DNA, 3 μM of sense and antisense oli-
gonucleotides, and 5 μl of HotStart Master Mix 
(Qiagen) in a final volume of 10 μl. PCR products 
were sequenced in both directions with the use 
of the Big Dye terminator kit (version 1.1, Applied 
Biosystems) and an automated capillary sequenc-
er (ABI PRISM 3130xl Genetic Analyzer, Applied 
Biosystems). We compared electrophoretogram-
derived sequences with reference sequences for 
NT5E (Ensembl gene number ENSG00000135318) 
by using Sequencher software (version 4.8). Screen-
ing of 200 DNA samples from controls of white 
race (panel HD200CAU, Coriell Cell Repositories) 
was performed by means of the 5′−nuclease al-
lelic discrimination (TaqMan) assay, as previ-
ously described.8 Details of the PCR amplifica-
tion, primer sequences, and allelic discrimination 
assay are available in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org.
Expression Studies
RNA was isolated from cultured fibroblasts with 
the use of the RNeasy kit (Qiagen), and comple-
mentary DNA (cDNA) was generated from 1-μg 
RNA samples with the use of the SuperScript II 
Reverse Transcriptase kit (Invitrogen). Expression 
of NT5E was measured by means of a quantitative 
real-time PCR assay involving SYBR Green tech-
nology on a Chromo4 Real Time PCR Detection 
System (Bio-Rad). Expression levels were calculat-
ed on the basis of the 2−ΔCt method, in which the 
cycling threshold (Ct) of the candidate gene is 
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compared with the Ct of 18S ribosomal RNA and 
expressed as a power of two (2(Ct of CD73−Ct of 18S)). 
Primer sequences for NT5E and 18S rRNA are 
provided in the Supplementary Appendix.
Western Blotting for CD73
Western blotting methods are described in the 
Supplementary Appendix.
CD73 Enzyme Assay
Fibroblasts were washed with a solution of 2 mM 
magnesium chloride, 120 mM sodium chloride, 
5 mM potassium chloride, 10 mM glucose, and 
20 mM HEPES. Incubation buffer, consisting of 
the wash solution supplemented with 2 mM AMP, 
was added, and cells were incubated at 37°C for 
10 minutes.9 The supernatant was removed, and 
inorganic phosphate was measured with the 
SensoLyte MG Phosphate Assay Kit (AnaSpec) ac-
cording to the manufacturer’s instructions. Inor-
ganic phosphate measurements were normalized 
to micrograms of protein.
Cloning of Mutations and Production  
of Lentivirus
The plasmid pCMV-Sport6 containing human 
CD73 cDNA was purchased from Open Biosystems. 
Mutations were introduced by means of the 
QuikChange XL Site-Directed Mutagenesis Kit 
(Stratagene). Primer sequences used for site-direct-
ed mutagenesis for each family are provided in 
the Supplementary Appendix.
Construct sequences were confirmed by se-
quencing in both directions. Since the pCMV-
Sport6 vector contains Gateway cloning (Invitro-
gen) recombination sites, we used this cloning 
strategy to insert normal and mutated CD73 cDNA 
into the vector pLenti6.3/V5-DEST; lentivirus was 
generated with the use of the ViraPower HiPer-
form Lentiviral Gateway Expression Kit (Invitro-
gen). For transduction, viral particles were added 
to cells in growth medium containing 6 μg of 
polybrene per milliliter (Sigma). To select for cells 
transduced with virus, blasticidin (Invitrogen; 
10 μg per milliliter) was added to growth medi-
um 4 days after transduction.
Transfection into HEK293 Cells
HEK293 cells (from human embryonic kidneys) 
were cultured in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% fetal-calf serum and 
1% penicillin–streptomycin. One microgram of 
pCMV-Sport6 containing green fluorescent pro-
tein, wild-type NT5E cDNA, or mutated NT5E cDNA 
was transfected into HEK293 cells with the use 
of FuGENE 6 reagent (Roche) according to the 
manufacturer’s instructions. Three days after 
transfection, cells were analyzed for CD73 activ-
ity, as described above.
In Vitro Alkaline Phosphatase and Calcium 
Assays
Staining for alkaline phosphatase was performed 
by means of the Alkaline Phosphatase Detection 
Kit (Millipore). Assay of alkaline phosphatase was 
performed with the use of the Quantitative Alka-
line Phosphatase ES Characterization Kit (Milli-
pore) according to the manufacturer’s instruc-
tions. Briefly, cells were trypsinized and collected 
in aliquots of 60,000 cells per reaction in p-nitro-
phenol–phosphate substrate. Alkaline phospha-
tase was quantified by measuring the amount of 
p-nitrophenol produced, as gauged by absorption 
at 405 nm.
A modified protocol for in vitro calcification 
was used for fibroblasts obtained from patients 
and controls.10,11 Cultures were treated with 
0.1 μM dexamethasone, 50 μM ascorbic acid– 
2-phosphate, and 10 mM β-glycerol phosphate in 
alpha minimal essential medium supplemented 
with 10% fetal-calf serum and 1% penicillin–
streptomycin for 21 days, with replenishment of 
the medium every 4 or 5 days. On day 21, cells 
were washed with phosphate-buffered saline and 
fixed in 10% formalin for 10 minutes. After wash-
ing with water, a solution of 2% alizarin red S, 
pH 4.2, was used to stain calcium phosphate 
crystals.12
R esult s
Case Reports
Full clinical details of the study families are pro-
vided in the Supplementary Appendix. Family 1 
was of English descent. The proband (Fig. 1A), 
Patient VI.1, was a 54-year-old woman with a 20-
year history of intermittent claudication of the 
calves, thighs, and buttocks and chronic ischemic 
pain in the feet at rest. Her parents were third 
cousins. On evaluation at the NIH, her ankle–
brachial blood-pressure index values were mark-
edly reduced, but the levels of serum calcium, 
phosphate, vitamin D, alkaline phosphatase, cre-
atinine, and cholesterol, and other chemical val-
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ues were normal (Table 1). Contrast-enhanced 
magnetic-resonance angiography revealed exten-
sive occlusion of the iliac, femoropopliteal, and 
tibial arteries, with extensive collateralization. 
Plain radiography of the lower extremities revealed 
heavy calcification with areas of arteriomegaly 
(Fig. 1B and 1C); chest radiography revealed no 
vascular calcifications above the diaphragm. Ra-
diography also revealed juxta-articular joint-cap-
sule calcifications of the fingers (Fig. 1D), wrists, 
ankles, and feet.
All four siblings of Patient VI.1 had disabling 
intermittent claudication (ability to walk only 
1 to 6 blocks) and hemodynamically significant 
lower-extremity obstructive peripheral artery dis-
ease, with resting ankle–brachial blood-pressure 
B C
D
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VII
VIII
1 2
1 3 4 52
Family 1
Family 1,
Patient VI.1
Family 2,
Patient II.4
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I
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Figure 1. Pedigrees of the Study Patients and Radiographic Findings.
Panel A shows the pedigrees of the three study families. Open symbols indicate unaffected family members, and solid red symbols af-
fected members. Arrows indicate the probands. Squares indicate male family members, circles female members, slashes deceased 
members, and double horizontal lines consanguinity. The diamond indicates offspring of unknown number, and the triangle a lost preg-
nancy. Panel B shows plain radiographs of popliteal arteries of the three probands. Panel C shows plain radiographs of the pelvis and fe-
murs (left) and ankle (right) of Patient VI.1 of Family 1, revealing calcified arteries (arrow). Panel D shows radiographs of metacarpal 
phalangeal and interphalangeal joint calcification (arrow) in Patient VI.1 of Family 1.
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index values between 0.3 and 0.8 (normal range, 
1.0 to 1.3). All had extensive femoropopliteal oc-
clusion evident on magnetic-resonance arteriog-
raphy, with diffuse, mild aneurysmal remodeling 
in a pattern of arteriomegaly. Computed tomo-
graphic (CT) angiography in three of the siblings 
showed that the obstructive lesions were diffusely 
and heavily calcified. Whole-body CT scanning for 
calcium, performed in one sister (Patient VI.5), 
showed prominent circumferential vascular calci-
fications in the lower extremities; CT angiogra-
phy revealed extensive vascular obstruction with 
diffuse calcification (see the video, available at 
NEJM.org).
The proband of Family 2 (Fig. 1A), Patient II.4, 
was a 68-year-old northern Italian woman whose 
mother’s surname was the same as that of some 
of her father’s relatives four generations ago. She 
reported having intense joint pain in her hands 
that was unresponsive to glucocorticoids admin-
istered from 14 to 27 years of age. Radiographs of 
the lower limbs revealed calcifications (Fig. 1B), 
initially diagnosed as chondrocalcinosis. Serum 
electrolyte, calcium, and cholesterol levels were 
normal. Two sisters, 73 and 70 years of age (Fig. 
1A), also had lower-extremity pain and had vas-
cular calcifications that were similar to those of 
the proband.
The proband of Family 3 (Fig. 1A), Patient II.1, 
was a 44-year-old woman with an English father 
and a French mother. At 42 years of age, mild 
paresthesias in the lower legs prompted an evalu-
ation that revealed extensive calcifications of the 
distal arteries (Fig. 1B), with sparing of the carotid 
arteries, aorta, and coronary arteries. Extensive 
rheumatologic evaluations were negative. Concern 
about impending ischemia in the right leg prompt-
ed a femoral–popliteal bypass at 43 years of age. 
Serum C-reactive protein, cholesterol, lipid, calci-
um, phosphate, and vitamin D levels were within 
the normal range.
None of the nine affected patients and none of 
their parents or children had abnormal bone mor-
phologic characteristics, type 2 diabetes mellitus, 
or decreased kidney function. The parents of the 
five siblings in Family 1 had no clinically signifi-
cant calcifications in their lower extremities or 
joint capsules.
SNPs, Mutation Analyses, and Expression Studies
We identified biallelic nonsense, missense, and 
single-nucleotide insertion–frameshift mutations 
in the ecto-5′-nucleotidase gene NT5E, encoding 
the CD73 enzyme, which generates extracellular 
adenosine, directly downstream of ENPP1 in the 
extracellular ATP–degradation pathway.
The consanguineous pedigree of Family 1, with 
disease confined to one generation (Fig. 1A), sug-
gested autosomal recessive inheritance. Therefore, 
we searched for a region of the genome in which 
all five affected siblings were homozygous and 
identical by means of descent but in which both 
parents were heterozygous. There was only one 
such region in the entire genome: a 22.4-Mb re-
gion (Fig. 2A) on chromosome 6q14 (86,157,551 to 
108,573,717 bp), containing 7977 genotyped SNPs 
and 92 genes. The lod score for the region in this 
family, calculated with the use of parametric 
multipoint linkage analysis, was 4.81.
Of the 92 genes in this region, 3 were evaluated: 
ATG5 and CASP8AP2 because they are involved in 
degenerative cellular processes that could lead to 
calcification, and NT5E because its enzyme sub-
strate is the product of ENPP1, mutations in which 
cause arterial calcifications in infants.5 Direct se-
quencing identified a homozygous nonsense mu-
tation (c.662C→A, resulting in p.S221X) in exon 3 
of the NT5E gene in all five siblings of Family 1 
and the same nonsense mutation in the hetero-
zygous state in both parents (Fig. 2B). Quantita-
tive PCR analysis documented decreased expres-
sion of NT5E messenger RNA in the fibroblasts 
of Patients VI.1 and VI.4 in Family 1 (Fig. 2C). 
Affected members of Family 2 were homozygous 
for a missense mutation, c.1073G→A (p.C358Y), 
in exon 5 of NT5E; the mother was heterozygous 
for this variant of the amino acid, which is con-
served across 16 species (Fig. 1A in the Supplemen-
tary Appendix). The affected member of Family 3 
was a compound heterozygote for the c.662C→A 
nonsense mutation found in Family 1 and a 
c.1609dupA (V537fsX7) mutation leading to a pre-
mature stop codon in exon 9 of NT5E (Fig. 1B in 
the Supplementary Appendix). None of these mu-
tations was present in 400 alleles in ethnically 
matched controls.
Protein and Enzyme Activity
NT5E encodes CD73, a membrane-bound ecto-5′-
nucleotidase (specifically, 5′–ribonucleotide phos-
phohydrolase; EC 3.1.3.5) involved in extracellular 
ATP metabolism. The enzyme preferentially binds 
AMP and converts it to adenosine and inorganic 
phosphate.13
Protein analysis involving Western blotting of 
fibroblast extracts from Patients VI.1 and VI.4 of 
A video showing 
diffuse vascular 
calcification 
is available at 
NEJM.org 
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Figure 2. Results of Genetic and Enzyme Studies in Family 1.
Panel A shows single-nucleotide polymorphism (SNP)–array homozygosity plots for the five affected siblings in 
Family 1 and their parents. The five affected siblings shared a region in which heterozygosity was absent, reflecting 
identity by means of descent in this consanguineous family. Panel B shows sequence chromatograms for a control, 
a parent of an affected member of Family 1, and an affected member; the nonsense mutation (p.S221X) is indicat-
ed. Panel C shows NT5E messenger RNA (complementary DNA [cDNA]) expression in Patients VI.4 and VI.1 as 
compared with controls. Panel D shows a deficiency in CD73 enzyme activity (represented by AMP-dependent inor-
ganic phosphate production) in cultured fibroblasts from Patient VI.4 and Patient VI.1 of Family 1. Panel E shows 
CD73 enzyme activity in fibroblasts from controls and from Patient VI.4 after the fibroblasts were transduced with 
either an empty vector (containing green fluorescent protein only) or a CD73-containing vector. The CD73 vector in-
creased CD73 activity (represented by AMP-dependent inorganic phosphate production) in both the control cells 
and the patients’ cells. Panel F shows CD73 activity (represented by AMP-dependent inorganic phosphate produc-
tion) in HEK293 cells transfected with an empty vector or a vector containing wild-type NT5E or NT5E with the 
c.622C→A, c.1073G→A, or c.1609dupA mutation or both the c.622C→A and c.1609dupA mutations (in a 1:1 ratio, 
simulating the state in Patient II.1 of Family 3). In Panels C, D, and F, data are the means of three experiments and 
were analyzed with the use of one-way analysis of variance with Dunnett’s multiple-comparison post hoc test. In 
Panel E, data are the means of three experiments and were analyzed with the use of an unpaired Student’s t-test. 
P values are shown for the comparison with controls in Panels C and D and with the various mutated cDNA in Panel 
F. In Panels C through F, I bars indicate the standard deviations.
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Family 1 revealed markedly reduced expression of 
CD73 protein, as compared with normal controls 
(Fig. 2 in the Supplementary Appendix). An enzy-
matic assay of CD73 in fibroblasts from our pa-
tients revealed nearly absent activity (Fig. 2D); val-
ues for fibroblasts from the patients’ parents were 
approximately 72% of the control level (Fig. 3 in 
the Supplementary Appendix). Genetic rescue with 
a CD73-encoding lentiviral vector reestablished 
normal AMP-dependent inorganic phosphate pro-
duction (Fig. 2E). The enzymatic activities of nor-
mal and mutant CD73 constructs were tested in 
HEK293 cells, which have low endogenous CD73 
activity. Transfection with normal NT5E cDNA re-
sulted in abundant CD73 activity, whereas trans-
fection with the c.662C→A NT5E, c.1073G→A NT5E, 
or c.1609dupA NT5E yielded negligible produc-
tion of AMP-dependent inorganic phosphate 
(Fig. 2F).
Cellular Studies
A key enzyme in tissue calcification in vitro and 
in vivo is tissue-nonspecific alkaline phosphatase 
(TNAP).14 After 3 days of calcific stimulation, fi-
broblasts from Patient VI.4 of Family 1 stained 
abundantly for TNAP, as compared with control 
cells; treatment with adenosine substantially re-
duced the amount of TNAP staining (Fig. 3A). 
TNAP activity was also assayed in the lysates of 
fibroblasts grown in calcifying medium. As com-
pared with control cells, cells from Patient VI.4 
showed high levels of TNAP that were signifi-
cantly reduced after transduction with CD73-
encoded lentiviral vector or by adenosine treatment 
(Fig. 3B). Three weeks of calcific stimulation re-
sulted in abundant calcium phosphate crystal for-
mation in mutant fibroblasts (from Patient VI.4) 
but no formation in normal fibroblasts (Fig. 3C). 
Calcium phosphate crystal formation was pre-
vented in cells transduced with a CD73-encoding 
lentiviral vector but not control vector expressing 
β-galactosidase. Adenosine treatment largely ab-
rogated the calcification process, and the noncom-
petitive alkaline phosphatase inhibitor levamisole 
completely prevented calcification in the mutant 
cells (Fig. 3C).
Discussion
Medial arterial calcification of the lower extrem-
ities with periarticular calcification was described 
first by Magnus-Levy15 in 1914 and again by Levi-
tin16 in 1945. The familial nature of this condi-
tion was first suggested in a report on two affected 
siblings by Sharp17 in 1954, leading to a subse-
quent record in the Online Mendelian Inheri-
tance in Man database (OMIM number, 211800). 
Other, single cases were described by Nosaka and 
colleagues18 and Mori and coworkers,19 yielding 
a total of seven cases published to date. Here, we 
describe the molecular and enzymatic basis of 
this disorder in nine patients with three different 
mutations in NT5E.
Considerable evidence supports the associa-
tion of these families’ vascular disease with mu-
tations in the NT5E gene. The results of segrega-
tion analysis were consistent among our families, 
and the nonsense mutation (p.S221X) and single-
nucleotide insertion (p.V537fsX7) predict truncated 
CD73 proteins. The missense mutation (p.C358Y), 
which was not found in 200 unaffected persons, 
predicts a pathologic change in an amino acid 
conserved through evolution and is located in the 
critical nucleotidase domain of CD73. Further-
more, the nonsense mutation resulted in mark-
edly reduced levels of CD73 mRNA and protein 
in cultured cells. Enzyme activity was virtually 
absent in fibroblasts from affected members of 
Family 1 and was rescued by transduction of a 
lentiviral vector expressing NT5E. Each of the 
three different mutations in the three families 
produced essentially nonfunctional CD73.
CD73 participates in the extracellular pathway 
that converts ATP to adenosine on the surface of 
various types of cells, as follows. First, ENPP1 
produces AMP and pyrophosphate from ATP; then 
CD73 produces adenosine and inorganic phos-
phate from AMP (Fig. 4). Cellular calcification 
depends critically on levels of pyrophosphate, a 
strong inhibitor of calcification, and TNAP, which 
degrades pyrophosphate.14 In patients with hypo-
phosphatasia due to TNAP deficiency, increased 
levels of pyrophosphate result in defective bone 
mineralization.20 In patients with generalized arte-
rial calcification of infancy, ENPP1 deficiency leads 
directly to decreased pyrophosphate levels,21 caus-
ing early-onset vascular calcification, myocardial 
infarction, and often death in infancy.5 In our 
adult patients, CD73 deficiency may not lead di-
rectly to decreased pyrophosphate levels, but the 
consequent reduction in extracellular adenosine 
levels apparently enhances TNAP activity; ade-
nosine supplementation reversed the increase in 
TNAP activity in CD73-deficient cells. We hy-
pothesize that increased TNAP activity reduces 
pyrophosphate levels, leading to calcification; 
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indeed, levamisole, an inhibitor of TNAP, pre-
vented calcium crystal formation by CD73-defi-
cient fibroblasts. The selective involvement of 
lower-extremity arteries may be related to the 
particular distribution of adenosine receptors in 
these tissues.22
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Figure 3. Studies of Fibroblasts Obtained from Patient VI.4 of Family 1.
Panel A shows the results of staining for tissue-nonspecific alkaline phosphatase (TNAP) in fibroblasts from a con-
trol and from Patient VI.4 after incubation for 3 days in calcifying medium. The increased staining in the patient’s 
cells (middle image) was reduced by adding 30 μM adenosine to the incubation medium daily (right image). Panel B 
shows TNAP activity in fibroblasts from a control and from Patient VI.4 after incubation for 3 days in calcifying me-
dium. Transduction with a control vector expressing β-galactosidase had little effect on alkaline phosphatase activi-
ty, whereas transduction with a CD73-encoding vector reduced alkaline phosphatase activity significantly; incuba-
tion in 30 μM adenosine produced TNAP levels similar to those seen in control cells. The data shown are the means 
of three experiments and were analyzed by means of analysis of variance with Dunnett’s multiple-comparison post 
hoc test. P values are shown for the comparison with no treatment. I bars indicate standard deviations. Panel C 
shows the effects of interventions on calcium phosphate crystal formation in fibroblasts from a control and from 
Patient VI.4. Staining for calcium with alizarin red S showed abundant staining in the patient’s cells, as compared 
with no staining in control cells, after 21 days in calcifying medium. Calcium staining was prevented by transduction 
with a CD73-encoding lentiviral vector, but not a control vector expressing β-galactosidase, and by treatment every 
fourth day with 1 mM levamisole; daily treatment with 30 μM adenosine partially abrogated the calcification process.
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Knowledge of the basic defect in our patients 
allows for consideration of therapeutic interven-
tions. Bisphosphonates, which are pyrophosphate 
analogues and potent inhibitors of tissue calcifi-
cation, have been successfully used to treat ENPP1 
deficiency and might prove beneficial in patients 
with CD73 deficiency.23,24 Dipyridamole, an anti-
thrombotic drug used successfully in patients with 
aneurysmal vascular remodeling, could provide 
adenosine rescue, since it inhibits cellular reup-
take of adenosine (and subsequent degradation 
by adenosine deaminase) both in vitro and in 
vivo.25 Other therapeutic possibilities include the 
use of adenosine-receptor agonists or a direct 
inhibitor of TNAP such as lansoprazole.26,27 The 
potential efficacy of such interventions can be 
investigated in cultured cells, which exhibit both 
TNAP and calcification phenotypes that are ab-
rogated by transduction with a CD73-encoded 
lentiviral vector. Mice with CD73 deficiency can 
also be studied, if a calcification phenotype can 
be discerned,28,29 to elucidate the role of adeno-
sine in regulating vascular calcification, influenc-
ing bone mineralization, and modulating ectopic 
calcium deposition.
In summary, we identified mutations in NT5E
in members of three families with symptomatic 
arterial and joint calcifications. This gene encodes 
CD73, a nucleotidase that converts AMP to adeno-
sine. Thus, our results support a role for this 
metabolic pathway in inhibiting ectopic tissue 
calcification.
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Figure 4. Proposed Mechanism of Mineralization 
Due to CD73 Deficiency from an NT5E Mutation.
On the surface of vascular cells, ENPP1 (the protein 
encoded by the ectonucleotide pyrophosphatase–
phosphodiesterase 1 gene) converts ATP to AMP and 
pyrophospha e (PPi), nd CD73 converts AMP to aden-
osine and inorganic phosphate (Pi). Pyrophosphate 
inhibits calcification, tissue-nonspecific alkaline phos-
phatase (TNAP) degrades pyrophosphate, and adeno-
sine inhibits TNAP. Deficiency of CD73 results in de-
creased adenosine levels, eliminating the inhibition 
of TNAP from the pathway either directly or by way of 
adenosine receptor signaling. Increased TNAP from 
the pathway activity results in decreased pyrophos-
phate and increased cell calcification.
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